Back to News
Market Impact: 0.2
Tango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung Cancers
Source: Nasdaq
Healthcare & Biotech
Tango Therapeutics and Erasca opened enrollment in a Phase 1/2 trial combining vopimetostat with ERAS-0015 in genetically defined pancreatic and lung cancers. The announcement provides no enrollment target, results, or other trial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ERAS0.35
TNGX0.35
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Truist raises Vericel stock price target on MACI growth momentum
- Humana lifts annual profit forecast as medical costs ease